Expert Discusses Studying irAEs in Patients With ICC

November 26, 2019
Sarah Abou Alaiwi, MD

With new immune checkpoint inhibitors being utilized in treating patients with ICC, physicians need to study new ways to address irAEs associated with this treatment.

With the continued use and breakthrough of immune checkpoint inhibitors in many different types of cancers, it’s now on researchers and physicians to find ways to study and manage immune-related adverse events as best they can, according to Sarah Abou Alaiwi, MD.

Alaiwi, a research fellow in medicine at the Dana-Faber Cancer Institute, had the chance to present at the 18th International Kidney Cancer Symposium on new treatment updates in intrahepatic cholangiocarcinoma (ICC) and how immunotherapy plays a role treating patients with ICC.

In an onsite interview with OncLive®, a sister publication to Oncology Nursing News®, Alaiwi had the chance to discuss what needs to happen for patients with ICC, and other cancers, utilizing immune checkpoint inhibitors to have a better quality of life.

TRANSCRIPTION

I imagine that it is now up to the medical oncologists and the treating physicians to sit down and put forward some efforts, and I think being together at the kidney cancer symposium is actually a great step to do that. And just looking at what are some ways that we can actually study those immune-related adverse events in a controlled environment. And so, it's just about now, if oncologists can kind of sit down together and not only in ICC, but across all diseases are all tumors, where a new checkpoint inhibitor is approved for therapy.